Please assess the completion status of the following clinical trial:

Trial Title: Insulin Therapy for Post-transplant Glucocorticoid Induced Hyperglycemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Have undergone bone marrow, liver, lung, or renal transplant.~2. Be using once daily oral glucocorticoid therapy (total daily dose of Prednisone ≥10 mg, Hydrocortisone ≥40 mg, Dexamethasone ≥1.5 mg) administered in the morning and expected to continue for at least 2 weeks.~3. Have pre-existing or newly diagnosed diabetes mellitus established by any of the criteria listed below:~   1. Fasting plasma glucose ≥7.0 mmol/L (repeated x 1)~  2. Any plasma glucose ≥11.0 mmol/L~4. Have at least three pre-meal inpatient capillary blood glucose (CBG) readings ≥ 7.8 mmol/L~5. Be eating meals by mouth~Exclusion Criteria:~1. Heart, Pancreas, Islet cell transplant recipients~2. Previous use of Basal-Bolus or Pre-Mixed Insulin regimen~3. Diabetes mellitus type I~4. NPO (not eating meals by mouth)~5. Receiving enteral (tube feeds) or parenteral (TPN) nutrition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neutral protamine hagedorn (NPH) insulin (Type: ACTIVE_COMPARATOR): Drug: Neutral protamine hagedorn (NPH) insulin~Other Names:~Humulin N, Novolin N~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before breakfast; Duration: 12 hours; for duration subjects are concurrently administered once-daily glucocorticoid.
- Regular or Aspart insulin (Type: EXPERIMENTAL): Drug: Regular human insulin or Insulin Aspart~Other Names:~Humulin R, Novolin R, Novolog, NovoRapid~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before meals; Duration: 2 hours (Aspart) or 6 hours (Regular); for duration subjects are concurrently administered once-daily glucocorticoid.
- Insulin glargine (Type: EXPERIMENTAL): Drug: Insulin glargine~Other Names:~Lantus~Route: Subcutaneous; Dosage: No fixed dose, varies between subjects; Frequency: daily before breakfast; Duration: 24 hours; for duration subjects are concurrently administered once-daily glucocorticoid.

Based on this trial design, predict the completion outcome and termination type (if applicable).